 Nes-Ziona, Israel, June 18, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office JPO has issued a notice of allowance for a patent application covering ALLOCETRATM, the companys immunotherapy product candidate. The company expects the new patent to issue in Japan during the third quarter of 2020. Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. 